Review




Structured Review

ClinRisk Ltd open and closed-source software
Open And Closed Source Software, supplied by ClinRisk Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/open+and+closed+source+software/open+and+closed+source+software/pmc11739568-294-5-0
Average 90 stars, based on 1 article reviews
open and closed-source software - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Software:

Article Title: Factors influencing influenza, pneumococcal and shingles vaccine uptake and refusal in older adults: a population-based cross-sectional study in England
Article Snippet: .. JH-C has received grants from the National Institute for Health Research Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund, Cancer Research UK (grant number C5255/A18085) through the Cancer Research UK Oxford Centre, and the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z) during the conduct of the study, is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health who supply the QResearch database used for this work, and is a founder and shareholder of ClinRisk and was its medical director until 31 May 2019; ClinRisk produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. ..

Article Title: Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people.
Article Snippet: JH-C is co-owner of ClinRisk Ltd and was a paid director until June 2019. .. ClinRisk Ltd develops open and closed source software to ensure the reliable and updatable implementation of clinical risk equations within clinical computer systems to help improve patient care outside the submitted work. ..

Article Title: NHS Health Checks: an observational study of equity and outcomes 2009–2017
Article Snippet: .. Julia Hippisley-Cox is the director of ClinRisk Ltd, which produces open and closed source software to ensure the reliable and updatable implementation of clinical risk algorithms (including QRisk2) within clinical computer systems to help improve patient care. .. Carol Coupland is a consultant statistician for ClinRisk Ltd.

Article Title: Effectiveness and safety of COVID-19 vaccination in people with blood cancer.
Article Snippet: .. JHC is founder and was shareholder until 9 Aug 2023 of ClinRisk Ltd, which produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. ..

Article Title: Importance of accurate and accessible recording of healthcare contacts in mental health.
Article Snippet: .. JHC was also a paid director of ClinRisk Ltd. which produces open and closed source software to ensure the reliable and updatable implementation of clinical risk equations within clinical computer systems to help improve patient care. ..

Article Title: Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England.
Article Snippet: JHC is a founder and shareholder of ClinRisk ltd and was its medical director until 31st May 2019. .. ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. ..

Article Title: Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the QResearch® database: research protocol and statistical analysis plan.
Article Snippet: .. ClinRisk Ltd. produces open and closed source software to implement clinical risk algorithms into clinical computer systems including the original QCancer algorithms referred to above. ..

other:

Article Title: Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
Article Snippet: Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the NIHR for the submitted work; JH-C reports grants from NIHR Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK, through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund and other research councils, during the conduct of the study; JH-C is an unpaid director of QResearch, a not-for-profit organisation that is a partnership between the University of Oxford and EMIS Health, which supplied the QResearch database used for this work; JH-C is a founder and shareholder of ClinRisk and was its medical director until 31 May 2019 (ClinRisk produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems); JH-C is chair of the NERVTAG risk stratification subgroup and a member of SAGE covid-19 groups and the NHS group advising on prioritisation of use of monoclonal antibodies in covid-19 infection; CACC reports receiving personal fees from ClinRisk outside this work, and is a member of the NERVTAG risk stratification subgroup; KK is supported by the NIHR Applied Research Collaboration-East Midlands and the Leicester BRC and is a member of SAGE; RHK was supported by a UKRI Future Leaders Fellowship (MR/S017968/1); KD-O was supported by a grant from the Alan Turing Institute Health Programme (EP/T001569/1); AS is a member of the Scottish Government Chief Medical Officer’s covid-19 advisory group and a member of AstraZeneca’s thrombotic thrombocytopenic advisory group (both roles are unremunerated); RAL is a member of the Welsh government covid-19 technical advisory group (unrenumerated); MGS reports grants from Department of Health and Social Care NIHR UK, grants from the UK Medical Research Council, grants from Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, during the conduct of the study, and other funds from Integrum Scientific, Greensboro, NC, USA, outside the submitted work; MGS is a member of NERVTAG and attends SAGE covid-19; AH is a member of NERVTAG and the NHS group advising on prioritisation of use of monoclonal antibodies in covid-19 infection; JV is national clinical director for diabetes and obesity at NHS England and Improvement; FK is a member of the Northern Ireland Chief Medical Officer’s pandemic modelling group and strategic intelligence group; JSN-V-T is seconded to the Department of Health and Social Care, England.



Similar Products

90
ClinRisk Ltd open and closed-source software
Open And Closed Source Software, supplied by ClinRisk Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/open+and+closed+source+software/open+and+closed+source+software/pmc11739568-294-5-0
Average 90 stars, based on 1 article reviews
open and closed-source software - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ClinRisk Ltd open and closed source software
Open And Closed Source Software, supplied by ClinRisk Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/open+and+closed+source+software/open+and+closed+source+software/pm38359496-197-17-11
Average 90 stars, based on 1 article reviews
open and closed source software - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results